Laryngoscope. 2010 Feb;120(2):432-5.

Hereditary hemorrhagic telangiectasia/avastin.

Source

Department of Head and Neck Surgery, San Diego School of Medicine, University of California, VA San Diego Healthcare System, San Diego, California 92161, USA. tdavidson@ucsd.edu

Abstract

This is the first scientific report of hereditary hemorrhagic telangiectasia (HHT) epistaxis treatment by intranasal spraying of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). Epistaxis in patients with HHT is a morbid, mortal condition that is difficult and unpleasant to manage. Nasal telangiectasia growth is modulated by VEGF, which is elevated in HHT patients. Bevacizumab is a VEGF inhibitor that diminishes epistaxis when administered intravenously or injected locally, or as reported here when sprayed topically onto the nasal mucosa.

Comment in

Laryngoscope. 2010 Oct;120(10):2134.

PMID:: 19998344; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Case Reports

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

hereditary hemorrhagic telangiectasia - Genetics Home Reference

Supplemental Content

Save items

Related citations in PubMed

In reference to hereditary hemorrhagic telangiectasia/avastin. [Laryngoscope. 2010]
In reference to hereditary hemorrhagic telangiectasia/avastin.
Bachmann-Harildstad G. Laryngoscope. 2010 Oct; 120(10):2134.
Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. [Laryngoscope. 2011]
Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Karnezis TT, Davidson TM. Laryngoscope. 2011 Mar; 121(3):636-8. Epub 2010 Dec 16.
Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. [Laryngoscope. 2011]
Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Chen S 4th, Karnezis T, Davidson TM. Laryngoscope. 2011 Mar; 121(3):644-6. Epub 2010 Nov 11.
Review Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. [Laryngoscope. 2004]
Review Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia.
Jameson JJ, Cave DR. Laryngoscope. 2004 Apr; 114(4):705-9.
Review A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). [Curr Vasc Pharmacol. 2010]
Review A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
Zarrabeitia R, Albiñana V, Salcedo M, Señaris-Gonzalez B, Fernandez-Forcelledo JL, Botella LM. Curr Vasc Pharmacol. 2010 Jul; 8(4):473-81.

See reviews... See all...

Cited by 2 PubMed Central articles

Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. [Hum Antibodies. 2011]
Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies.
Kaja S, Hilgenberg JD, Everett E, Olitsky SE, Gossage J, Koulen P. Hum Antibodies. 2011; 20(3-4):95-101.
A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. [Case Rep Oncol. 2010]
A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab.
Amanzada A, Töppler GJ, Cameron S, Schwörer H, Ramadori G. Case Rep Oncol. 2010 Sep; 3(3):463-70. Epub 2010 Dec 11.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Hereditary hemorrhagic telangiectasia/avastin.
Hereditary hemorrhagic telangiectasia/avastin.
Laryngoscope. 2010 Feb ;120(2):432-5.

PubMed
Dietary fatty acids, luminal modifiers, and risk of colorectal cancer.
Dietary fatty acids, luminal modifiers, and risk of colorectal cancer.
Int J Cancer. 2010 Aug 15 ;127(4):942-51.

PubMed
Association of less common cystic fibrosis mutations with a mild phenotype.
Association of less common cystic fibrosis mutations with a mild phenotype.
J Med Genet. 1991 Jan ;28(1):34-7.

PubMed
Metabolite stress and tolerance in the production of biofuels and chemicals: gen...
Metabolite stress and tolerance in the production of biofuels and chemicals: gene-expression-based systems analysis of butanol, butyrate, and acetate stresses in the anaerobe Clostridium acetobutylicum.
Biotechnol Bioeng. 2010 Apr 15 ;105(6):1131-47.

PubMed
Oculofacialbulbar palsy in mother and son: review of 26 reports of familial tran...
Oculofacialbulbar palsy in mother and son: review of 26 reports of familial transmission within the 'Möbius spectrum of defects'.
J Med Genet. 1991 Jan ;28(1):18-26.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: